The Medicines Co. Pulls European Application For Oritavancin
This article was originally published in The Pink Sheet Daily
Executive Summary
Specialty pharma plans to investigate antibiotic as single-dose, 1,200 mg therapy after FDA and EMEA turned down proposed 200 mg, multi-day dosing.